Cytomegalovirus Enterocolitis secondary to experimental COVID-19 therapy

Geisen, Will R.; Berger, Justin; Schwartz, Chelsea; Reddy, Abhimanyu; Rai, Balaj; Wadih, George; Peck, Joshua R.

doi:10.1016/j.idcr.2020.e00962

Cited by 13 publications

(14 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CMV reactivation, colitis and hypovolemic shock was observed in a critically ill patient undergoing experimental treatment for COVID-19. [65]. In studies of T cell activation to CMV peptides in vitro, there was a clear trend for enhanced activation of CD8 positive T cells from COVID-19 patients as compared with T cells from controls [66][67][68], but too few individuals were studied to demonstrate a statistical significance.…”

Section: Main Textmentioning

confidence: 99%

Does reactivation of cytomegalovirus contribute to severe COVID-19 disease?

Söderberg‐Nauclér

2021

Immun Ageing

View full text Add to dashboard Cite

The majority of people infected with SARS-CoV-2 are asymptomatic or have mild to moderate symptoms. However, for unknown reasons, about 15 % have severe pneumonia requiring hospital care and oxygen support, and about 5 % develop acute respiratory distress syndrome, septic shock, and multiorgan failure that result in a high mortality rate. The risk of severe COVID-19 is highest among those who are over 70 years of age. Why severe COVID-19 develops in some people but not others is not understood. Could some cases involve reactivation of latent cytomegalovirus (CMV)?

show abstract

Section: Main Textmentioning

confidence: 99%

Does reactivation of cytomegalovirus contribute to severe COVID-19 disease?

Söderberg‐Nauclér

2021

Immun Ageing

View full text Add to dashboard Cite

show abstract

“…Surveillance of rare safety issues related to these vaccines is progressing, since more granular data emerge about adverse events of SARS-CoV-2 vaccines during post-marketing surveillance ( 3 ). Varicella zoster virus (VZV), Epstein-Barr virus (EBV) and cytomegalovirus (CMV) reactivation has already been reported in COVID-19 patients ( 4 – 10 ). In addition, adverse events after SARS-CoV-2 mRNA vaccination have also been reported in the context of varicella zoster virus (VZV) reactivation and directly associated with the mRNA vaccine ( 11 , 12 ).…”

Section: Introductionmentioning

confidence: 99%

Case Report: Cytomegalovirus Reactivation and Pericarditis Following ChAdOx1 nCoV-19 Vaccination Against SARS-CoV-2

et al. 2022

View full text Add to dashboard Cite

As the coronavirus disease 2019 (COVID-19) pandemic is ongoing and new variants of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) are emerging, there is an urgent need for vaccines to protect individuals at high risk for complications and to potentially control disease outbreaks by herd immunity. Surveillance of rare safety issues related to these vaccines is progressing, since more granular data emerge about adverse events of SARS-CoV-2 vaccines during post-marketing surveillance. Varicella zoster virus (VZV), Epstein-Barr virus (EBV) and cytomegalovirus (CMV) reactivation has already been reported in COVID-19 patients. In addition, adverse events after SARS-CoV-2 mRNA vaccination have also been in the context of varicella zoster virus (VZV) reactivation and directly associated with the mRNA vaccine. We present the first case of CMV reactivation and pericarditis in temporal association with SARS-CoV-2 vaccination, particularly adenovirus-based DNA vector vaccine ChAdOx1 nCoV-19 against SARS-CoV-2. After initiation of antiviral therapy with oral valganciclovir, CMV viremia disappeared and clinical symptoms rapidly improved. Since huge vaccination programs are ongoing worldwide, post-marketing surveillance systems must be in place to assess vaccine safety that is important for the detection of any events. In the context of the hundreds of millions of individuals to be vaccinated against SARS-CoV-2, a potential causal association with CMV reactivation may result in a considerable number of cases with potentially severe complications.

show abstract

“…This report describes a critically ill patient with COVID‐19 who required reintubation and eventually died of secondary infection with CMV pneumonia. There are a limited number of published reports regarding co‐infection with SARS‐CoV‐2 and CMV, and these report have focused on gastrointestinal CMV disease [3–5]. To our knowledge, this is the first case of CMV pneumonia confirmed by a needle autopsy in a patient with COVID‐19.…”

Section: Discussionmentioning

confidence: 98%

Fatal cytomegalovirus pneumonia in a critically ill patient with COVID‐19

Amiya

Hirata

Shiroyama

et al. 2021

Respirology Case Reports

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID‐19) can cause severe lymphopenia and respiratory failure requiring prolonged invasive mechanical ventilation (MV). COVID‐19 patients with severe lymphopenia or respiratory failure are at risk of developing secondary infections. Here, we present the needle autopsy findings of a critically ill patient with COVID‐19 who required reintubation and prolonged MV, and eventually died of secondary cytomegalovirus (CMV) pneumonia. This case highlights the potential risk of long‐term steroid use and the need for routine monitoring for CMV infection in critically ill patients with COVID‐19.

show abstract

Cytomegalovirus Enterocolitis secondary to experimental COVID-19 therapy

Cited by 13 publications

References 11 publications

Does reactivation of cytomegalovirus contribute to severe COVID-19 disease?

Does reactivation of cytomegalovirus contribute to severe COVID-19 disease?

Case Report: Cytomegalovirus Reactivation and Pericarditis Following ChAdOx1 nCoV-19 Vaccination Against SARS-CoV-2

Fatal cytomegalovirus pneumonia in a critically ill patient with COVID‐19

Contact Info

Product

Resources

About